Leukocytosis and risk stratification assessment in essential thrombocythemia

Journal of Clinical Oncology

Volumn 26, Issue 16, 2008, Pages 2732-2736

  Carobbio, Alessandra ^a   Antonioli, Elisabetta ^a   Guglielmelli, Paola ^a   Vannucchi, Alessandro M ^a   Delaini, Federica ^a   Guerini, Vittoria ^a   Finazzi, Guido ^a   Rambaldi, Alessandro ^a   Barbui, Tiziano ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; JANUS KINASE 2;

ADOLESCENT; ADULT; AGED; ALLELE; ARTERY THROMBOSIS; ARTICLE; DISEASE ASSOCIATION; FEMALE; GENOTYPE; GROUPS BY AGE; HIGH RISK POPULATION; HUMAN; LEUKOCYTE; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; STATISTICAL MODEL; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOSIS; AGING; BLOOD; CHILD; CLASSIFICATION; CLINICAL TRIAL; ENZYMOLOGY; GENETICS; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; POLYCYTHEMIA VERA; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGING; CHILD; FEMALE; GENOTYPE; HUMANS; JANUS KINASE 2; LEUKOCYTOSIS; MALE; MIDDLE AGED; POLYCYTHEMIA VERA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOSIS;

EID: 45749098579     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.3569     Document Type: Article

References (17)

1. Cortelazzo S, Viero P, Finazzi G, et al: Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 8:556-562, 1990
2. Harrison CN, Campbell PJ, Buck G, et al: Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353:33-45, 2005
3. Vannucchi AM, Antonioli E, Guglielmelli P, et al: Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110:840-846, 2007
4. Carobbio A, Finazzi G, Guerini V, et al: Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: Interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 109:2310-2313, 2007
5. Gangat N, Wolanskyj AP, McClure RF, et al: Risk stratification for survival and leukemic transformation in essential thrombocythemia: A single institutional study of 605 patients. Leukemia 21:270-276, 2007
6. Tefferi A, Gangat N, Wolanskyj A: The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia. Blood 109:4105, 2007
7. Pencina MJ, D'Agostino RB: Overall C as a measure of discrimination in survival analysis: Model specific population value and confidence interval estimation. Stat Med 23:2109-2123, 2004
8. Harrell FE Jr, Lee KL, Mark DB: Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361-387, 1996
9. Wang TJ, Gona P, Larson MG, et al: Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 355:2631-2639, 2006
10. Antolini L, Boracchi P, Biganzoli E: A time-dependent discrimination index for survival data. Stat Med 24:3927-3944, 2005
11. Leisenring WM, Martin PJ, Petersdorf EW, et al: An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood 108:749-755, 2006
12. Landolfi R, Di Gennaro L, Barbui T, et al: Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 109:2446-2452, 2007
13. Falanga A, Marchetti M, Vignoli A, et al: V617F JAK-2 mutation in patients with essential thrombocythemia: Relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol 35:702-711, 2007
14. Coller BS: Leukocytosis and ischemic vascular disease morbidity and mortality: Is it time to intervene? Arterioscler Thromb Vasc Biol 25:658-670, 2005
15. Ware JH: The limitations of risk factors as prognostic tools. N Engl J Med 355:2615-2617, 2006
16. Wald NJ, Hackshaw AK, Frost CD: When can a risk factor be used as a worthwhile screening test? BMJ 319:1562-1565, 1999
17. Barbui T, Barosi G, Grossi A, et al: Practice guidelines for the therapy of essential thrombocythemia: A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 89:215-232, 2004